Michael Ryskin
Stock Analyst
(n/a)
# 4,642
Out of 4,650 analysts
34
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Michael Ryskin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEM Tempus AI | Downgrades: Neutral | $45 → $60 | $43.34 | +38.44% | 2 | Oct 2, 2024 | |
| GH Guardant Health | Maintains: Buy | $28 → $40 | $22.20 | +80.18% | 1 | Jul 18, 2024 | |
| ALIT Alight | Maintains: Buy | $10 → $9.5 | $7.18 | +32.31% | 1 | Jun 25, 2024 | |
| EXAI Exscientia | Downgrades: Neutral | $11 → $9 | $5.23 | +72.08% | 2 | Jan 5, 2024 | |
| MRVI Maravai LifeSciences Holdings | Upgrades: Buy | $10 → $8 | $7.21 | +10.96% | 2 | Dec 12, 2023 | |
| CERT Certara | Maintains: Buy | $27 → $24 | $10.42 | +130.33% | 2 | Aug 15, 2023 | |
| AVTR Avantor | Maintains: Buy | $27 → $24 | $22.64 | +6.01% | 2 | Jul 31, 2023 | |
| ALGN Align Technology | Maintains: Underperform | $190 → $225 | $215.80 | +4.26% | 5 | Apr 27, 2023 | |
| ZTS Zoetis | Maintains: Buy | $225 → $180 | $182.76 | -1.51% | 7 | Nov 4, 2022 | |
| OMIC Singular Genomics Systems | Downgrades: Underperform | $90 | $13.32 | +575.68% | 3 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $550 → $470 | $449.44 | +4.57% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.87 | - | 2 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $52 | $18.37 | +183.07% | 2 | Nov 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $17 → $10 | $4.29 | +133.10% | 2 | Nov 10, 2021 |
Tempus AI
Oct 2, 2024
Downgrades: Neutral
Price Target: $45 → $60
Current: $43.34
Upside: +38.44%
Guardant Health
Jul 18, 2024
Maintains: Buy
Price Target: $28 → $40
Current: $22.20
Upside: +80.18%
Alight
Jun 25, 2024
Maintains: Buy
Price Target: $10 → $9.5
Current: $7.18
Upside: +32.31%
Exscientia
Jan 5, 2024
Downgrades: Neutral
Price Target: $11 → $9
Current: $5.23
Upside: +72.08%
Maravai LifeSciences Holdings
Dec 12, 2023
Upgrades: Buy
Price Target: $10 → $8
Current: $7.21
Upside: +10.96%
Certara
Aug 15, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $10.42
Upside: +130.33%
Avantor
Jul 31, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $22.64
Upside: +6.01%
Align Technology
Apr 27, 2023
Maintains: Underperform
Price Target: $190 → $225
Current: $215.80
Upside: +4.26%
Zoetis
Nov 4, 2022
Maintains: Buy
Price Target: $225 → $180
Current: $182.76
Upside: -1.51%
Singular Genomics Systems
Aug 10, 2022
Downgrades: Underperform
Price Target: $90
Current: $13.32
Upside: +575.68%
May 5, 2022
Downgrades: Neutral
Price Target: $550 → $470
Current: $449.44
Upside: +4.57%
Apr 18, 2022
Downgrades: Neutral
Price Target: n/a
Current: $6.87
Upside: -
Nov 11, 2021
Downgrades: Neutral
Price Target: $80 → $52
Current: $18.37
Upside: +183.07%
Nov 10, 2021
Downgrades: Underperform
Price Target: $17 → $10
Current: $4.29
Upside: +133.10%